Citalopram — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Depression

• Fluoxetine
• Sertraline
• Bupropion XL
• Escitalopram

Other medications in Mental Health

• Clomipramine
• Clonazepam
• Clonidine
• Clorazepate
• Clozapine
• Desipramine
• Desvenlafaxine
• Dextroamphetamine

About Citalopram

Citalopram, commonly known by its brand name Celexa, is a widely prescribed antidepressant that helps countless individuals manage major depressive disorder and anxiety. At TheDrugClub, we believe mental health medication should be accessible and affordable for everyone. Citalopram is a medication primarily prescribed to treat Major Depressive Disorder (MDD). It can help alleviate symptoms such as persistent sadness, loss of interest in activities, changes in appetite or sleep, fatigue, and difficulty concentrating. While its primary use is for depression, healthcare providers may also prescribe citalopram off-label for conditions like Generalized Anxiety Disorder, Panic Disorder, or Obsessive-Compulsive Disorder, depending on individual patient needs and clinical judgment. ### How Citalopram Works

Citalopram belongs to a class of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs). Serotonin is a natural chemical in the brain that plays a crucial role in mood regulation, sleep, appetite, and overall well-being

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Citalopram is approved for (FDA label)

Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14) ] . Citalopram tablets are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ) .

Source: Read the full FDA label on DailyMed. Label effective date: July 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Citalopram (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . Citalopram tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) . Citalopram tablets are not approved for use in pediatric patients ( 8.4 ) .

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Citalopram (FDA label)

Citalopram Tablets, USP are available containing citalopram hydrobromide, USP equivalent to 10 mg, 20 mg or 40 mg citalopram. The 40 mg tablets are white, film-coated, round, scored tablets debossed with MX33 on one side of the tablet and a score line on the other side. Tablets: 40 mg, scored ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Citalopram (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity reactions [see Contraindications (4) ] Suicidal thoughts and behaviors in adolescents and young adults [see Warnings and Precautions (5.1) ] QT-prolongation and torsade de pointes [see Warnings and Precautions (5.2) ] Serotonin syndrome [see Warnings and Precautions (5.3) ] Increased risk of bleeding [see Warnings and Precautions (5.4) ] Activation of mania or hypomania [see Warnings and Precautions (5.5) ] Discontinuation syndrome [see Warnings and Precautions (5.6) ] Seizures [see Warnings and Precautions (5.7) ] Angle-closure glaucoma [see Warnings and Precautions (5.8) ] Hyponatremia [see Warnings and Precautions (5.9) ] Sexual Dysfunction [see Warnings and Precautions (5.10) ] Most common adverse reaction (incidence ≥ 5% and twice placebo) is ejaculation disorder (primarily ejaculation delay) ( 6.1 ) . To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Citalopram (FDA label)

Citalopram tablets are contraindicated in patients: taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . taking pimozide because of risk of QT prolongation [see Drug Interactions (7) ] . with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis [see Adverse Reactions (6.2) ] . Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of discontinuing a MAOI ( 4 ) . Concomitant use of pimozide ( 4 ) . Known hypersensitivity to citalopram or any of the inactive ingredients of citalopram tablets ( 4 ) .

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Citalopram (FDA label)

QT-Prolongation and Torsade de Pointes: Dose-dependent QTc prolongation, Torsade de pointes, ventricular tachycardia, and sudden death have occurred. Avoid use of citalopram tablets in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. Monitor electrolytes in patients at high risk for hypokalemia or hypomagnesemia. Discontinue citalopram tablets in patients with persistent QTc measurements > 500 ms ( 5.2 , 7 ) . Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone.

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Citalopram (FDA label)

Table 5 presents clinically important drug interactions with citalopram tablets. Table 5: Clinically Important Drug Interactions with Citalopram Tablets Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs, including citalopram tablets, and MAOIs increases the risk of serotonin syndrome.

Source: FDA prescribing information (DailyMed). Set ID: aa9c1440-354f-43a6-9e70-fd7bafcb03c5. SPL document ID: 579a40e5-ed64-65b2-e063-6394a90acec1. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.